Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial.
CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is enclosed in a virus‐like particle. It is designed to trigger innate and also adaptive anti‐tumor immune responses to convert immunologically “cold” tumors into immunologically “hot” tumors, with the potential to intervene in tumor regression.
The JAVELIN Medley study is sponsored by US pharma giant Pfizer in collaboration with German pharma company Merck.
According to Checkmate Pharmaceuticals , the JAVELIN Medley trial will assess BAVENCIO, a human anti-programmed death ligand (PD-L1) co-developed and co-commercialized by Merck and Pfizer, in combination with other immune modulators, including CMP-001, in patients having locally advanced or metastatic solid tumors.
Barry Labinger – President and CEO of Checkmate Pharmaceuticals said: “The dosing of patients in this trial represents an important milestone for Checkmate as we seek to build upon promising data we have generated to date with CMP-001, particularly in PD-1-refractory advanced melanoma.
“Based upon the preclinical and clinical work conducted to date, we believe CMP-001 can effectively convert cold tumors to hot and thereby improve response to PD-1/L1-based immunotherapy in a variety of solid tumors. We look forward to the results of this clinical trial.”
The phase 1b/2 clinical trial, which has enrolled up to 60 patients, will assess the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the doublet combination of avelumab and CMP-001, the triple combination of CMP-001, avelumab and utomilumab, and the triplet combination of CMP-001, avelumab and PF-04518600 in patients having locally advanced squamous cell cancer of the head and neck.